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Abstract
Background: Heavy kava use in Aboriginal commun-
ities has been linked to various health effects, including
anecdotes of sudden cardiac deaths.
Aims: To examine associations between kava use and
potential health effects.
Methods: A cross-sectional study was carried out within
a kava-using east Arnhem Land Aboriginal community
in tropical northern Australia. One-hundred-and-one
adults who were current, recent or non-users of kava
were enrolled in March 2000. Main outcome measures
were physical, anthropometric, biochemical, haemato-
logical, immunological and neurocognitive assessments.
Results: Kava users more frequently showed a charac-
teristic dermopathy (P < 0.001). They had increased
levels of γ-glutamyl transferase and alkaline phosphatase
(P < 0.001). Lymphocyte counts were significantly
lower in kava users (P < 0.001). Fibrinogen, plasmin-
ogen activator inhibitor-1 and neurocognitive tests were
not different between kava use categories. IgE and IgG
antibodies were elevated across the whole group, as were
C-reactive protein and homocysteine.
Conclusions: Kava use was associated with dermopathy,
liver function abnormalities and decreased lymphocytes.
If kava continues to be used by Aboriginal populations,
monitoring should focus on the health consequences of
these findings, including a possible increase in serious
infections. The interaction between kava, alcohol and
other substances requires further study. Although
markers of cardiovascular risk are increased across the
population, these were not higher in kava users, and this
increase may be linked to the large infectious pathogen
burden reflective of the socioeconomic disadvantage
seen in many remote Aboriginal communities. (Intern
Med J 2003; 33: 336–340)
Key words: Aboriginal people, C-reactive protein, 
immunoglobulins, kava, substance-related disorders.
INTRODUCTION
Kava, the intoxicating drink prepared from crushed roots
of the plant Piper methysticum, is widely used in South
Pacific countries on ceremonial occasions and in secular
drinking.1 Its effects on health became contentious when
it was introduced to Arnhem Land Aboriginal commun-
ities in 1982.2–4 In late 1999 there were perhaps 1050
people using kava in Arnhem Land in eight community
areas (A. Clough, unpubl. data, 2000).
A survey on kava use in Arnhem Land conducted in
1987 suggested additional health burdens to Aboriginal
populations. Kava use was associated with scaly skin and
users were more likely to be underweight. Users also had
decreased lymphocytes with increased γ-glutamyl trans-
ferase (GGT), high-density lipoprotein (HDL)-
cholesterol levels and decreased total protein, albumin,
urea and bilirubin.5
Recently it was suggested that kava use may be a risk
factor for sudden cardiac deaths among young Aborig-
inal sportsmen in Arnhem Land populations, especially
when coupled with heavy alcohol use.6,7 Possible mech-
anisms include abnormal coagulation with enhanced
thrombosis, dehydration or arrhythmias. Other health
risks for kava users include acute neurological effects8
and the infectious disease melioidosis, which may be
greater among heavy users.9,10 The aim of the present
study was to further investigate health effects of kava
consumption in an Arnhem Land community in tropical
northern Australia.
METHODS
A memorandum of understanding between the local
Aboriginal community Council and Menzies School of
Health Research guided the research. The Institutional
Ethics Committee of the Menzies School of Health
Research and Royal Darwin Hospital granted approval.
All participants gave written informed consent. Study
procedures were explained with the assistance of
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Aboriginal health workers. Clinicians in the study were
blinded to kava-using status of participants.
Community surveillance estimated that 75% of men
and 25% of women were kava users. From a population
of 150 men and 189 women, we were able to opportun-
istically recruit 101 consenting adults, a mix of male and
female subjects, approximately half were kava users.
Exposure to kava use was assessed by self-report in inter-
view compared with consensus classification by
community health workers along with health clinic
records using procedures already validated.11 These
were 38 current kava users (34 men, four women) who
reported using kava at least once in the month prior to
interview; 27 recent users (18 men, nine women) who
had had their last drink of kava prior to ‘last month’; and
36 people (13 men and 23 women) who reported that
they had never used kava. Information was also collected
on other substance use including alcohol, tobacco, petrol
sniffing and cannabis.
Subjects were examined for the presence of kava
dermopathy (a rash characteristic of heavy use), scabies,
skin sores (pyoderma) and tinea. Skin sores and tinea
were assessed and scored by counting the sites present,12
with maximum scores of 18 for skin sores and 41 for
tinea. Skin sores and tinea scores were categorized,
respectively, into mild (0–2) and (0–10); moderate (3–7)
and (11–20); and severe (7+) and (20+). Height and
weight were measured and body mass index (BMI)
calculated.13
Electrolytes, full blood count, urea, creatinine, liver
function tests, lipids (non-fasting), serum folate, iron
studies, homocysteine, fibrinogen, C-reactive protein
(CRP) and plasminogen activator inhibitor-1 (PAI-1)
were measured along with immunoglobulins and IgG
subsets. Eosinophilia was defined as an eosinophil count
of >0.6 × 109/L. Serum osmolality was calculated.14
Urine was tested using Boehringer dipsticks. Samples
‘positive’ for blood were sent for microscopy after adding
formalin. Numbers and percentages above and below
the normal range were calculated for current kava users
(Tables 1,2).
Neuropsychological assessments utilized the touch-
screen-based Cambridge Neuropsychological Test Auto-
mated Battery featuring minimum reliance on verbal
skills.15,16 Data were recorded as the proportion of
correct responses. Ocular motor function was assessed
with measures of latency and accuracy for prosaccades
(towards target) and antisaccades (away from target) and
an antisaccade error rate was calculated.
Statistical methods
Data were analysed using intercooled STATA (version 7;
Stata Corporation, College Station, TX, USA). Vari-
ables were compared across the three groups using one
way ANOVA or χ2 (exact) tests. Positively skewed data
were log-transformed before analysis.
RESULTS
A rash consistent with kava dermopathy was present in
45% of current kava users, 11% of recent users and 6%
338 Clough et al.
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of non-users (P < 0.001; Table 3). The two non-users
with such a rash probably reflect incorrect clinical
assessment rather than incorrect ascertainment of kava
consumption. Scabies, skin sores and tinea were higher
in current kava users but this was not statistically signif-
icant (P = 0.52, P = 0.11 and P = 0.53, respectively).
Mean BMI was lower among kava users and a greater
proportion of kava users (32%), compared with recent
users (15%) and non-users (14%) had a BMI < 18.5,
but more of the non-users were female. When female
subjects were excluded there was still a trend for kava
users to have lower BMI (P = 0.062).
There were no differences in neutrophils, monocytes
and eosinophils across the categories of kava use. Of the
group as a whole 25% had an eosinophilia. Lymphocyte
numbers were significantly lower (Tables 1,2) in current
and recent kava users (P < 0.001), with 51% of users
having a level below the normal range.
Creatinine levels tended to be higher among kava
users (P = 0.06) but there was no difference in calcu-
lated glomerular filtration rate (data not shown). The
following parameters showed no association with kava
use: urea, sodium, bicarbonate, chloride, inorganic
phosphate, calcium, uric acid, serum folate, fibrinogen
and PAI-1 (data not shown).
Cholesterol was significantly higher for current kava
users: 28% were over 5.5 mmol/L compared with 11%
for recent users and 11% for non-users. This remained
significant when comparing only male subjects. Interest-
ingly both HDL and low-density lipoprotein (LDL)
were significantly higher in current kava users. Triglyc-
erides were not significantly different between the
groups.
Serum osmolality was not significantly different across
the kava categories, although 17% of current kava users
had values lower than normal. The presence of dipstick
positive ‘blood’ was confirmed as true haematuria by
microscopy in only one of 24 cases.
Levels of GGT and alkaline phosphatase (ALP) were
above the normal range in 61% and 50% of kava users,
respectively. When data were log-transformed current
users had significantly higher GGT and ALP than recent
users and non-users (Tables 1,2). However there were
no differences between the groups in alanine trans-
aminase (ALT), bilirubin, albumin or total protein.
IgE was elevated in every individual tested from the
community and levels were significantly higher in
current and recent kava users (P = 0.02). Total IgG
levels (median: 18.1 g/L) were also all above normal but
were not different between the groups. Elevated IgG1
and IgG4 were responsible for the high levels
(Tables 1,2).
CRP and homocysteine were elevated in 36% and
16% overall, with no difference across the categories of
kava use. No significant differences were found for any
of the ocular motor or neuropsychological assessments
across the groups.
Kava use was associated with alcohol use (P < 0.001),
cannabis use (P < 0.001) and a history of petrol sniffing
(P = 0.035). Both cannabis and alcohol use remained
significant when comparing only male subjects. ThereTa
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was a trend for kava users to be tobacco smokers
(P = 0.076).
DISCUSSION
The study community is nominally ‘dry’ (alcohol is
prohibited), although retail outlets are located nearby so
illicit drinking occurs. There is concern that poly-
substance abuse is increasing in many Aboriginal
communities. In the present study, 82% of current kava
users smoked tobacco, 45% drank alcohol, 37% used
cannabis and 37% had a history of sniffing petrol. In the
study by Mathews et al. alcohol was a confounding
factor,5 which may have contributed to the abnormal
liver function tests. However, in the present study there
was a lack of association between alcohol use and GGT
and ALP (data not shown). Furthermore, several people
with abnormal liver function were heavy kava consumers
but did not drink alcohol.
Although there is currently no evidence for long-term
liver damage in regular kava users, this requires assess-
ment over longer periods, especially in heavy users.
Furthermore, the nature of the abnormal liver function
tests we observed remains to be elucidated. Elevated
GGT and ALP suggests the possibility of an obstructive
rather than an inflammatory pattern of response. In
Aboriginal people who cease kava drinking, abnormal
liver function tests return to normal after 1–2 months of
abstinence from kava use17 (B. Currie, unpubl. data,
2002). Importantly, the absence of an elevated ALT
suggests that in contrast with alcohol, acute inflam-
mation may not be occurring with kava use. However,
recent case reports of fulminant liver failure associated
with use of commercially available kava-based anxiety
treatments in Europe18 have resulted in kava-based
herbal products being withdrawn from sale in several
countries. This supports the need for further research
into the effects of kava on the liver.
The more frequent occurrence of abnormally low
lymphocyte levels coupled with higher IgE levels in
current and recent kava users are suggestive of an
immune system response. Elevated IgE and IgG levels in
the whole population are likely to reflect recurrent and
chronic bacterial and parasitic infections. The increases
in IgG1 and IgG4 are consistent with combined bacterial
and parasitic burdens, and elevated IgE levels and
eosinophil counts in the whole group are likely to reflect
the burden of intestinal parasites seen in remote Aborig-
inal communities.19 It is possible that the association of
heavy kava use with melioidosis9,10 may reflect increased
exposure to the wet season environmental pathogen
Burkholderia pseudomallei during prolonged sessions of
sitting in a kava circle consuming kava. Increased
parasite exposure in kava drinkers could also explain
higher IgE levels if they reflect a larger burden of
geohelminths such as Ancylostoma duodenale and Strongy-
loides stercoralis. But the consistently lower lymphocyte
counts in kava drinkers in this and the previous study5
warrant concern about a kava-related immunological
predisposition to certain infections such as melioidosis,
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for which diabetes and alcohol excess are known major
risk factors.8,10
Functional equivalence of neurocognitive assessments
across the groups suggests little if any deleterious effect
on the central nervous system. This is in contrast to
abnormalities found in petrol sniffers16 and heavy
alcohol users.20
Fibrinogen and PAI-1 are considered important
markers of potential thrombotic predisposition. There
was no association of these parameters with kava usage.
In addition, lipid profile was not clearly suggestive of
increased atheroma risk, with HDL being elevated as
well as cholesterol and LDL. The generally elevated
levels of CRP across the population studied suggest a
chronic systemic inflammatory response, possibly
reflecting increased exposure to various infectious path-
ogens. CRP is now recognized as an important marker of
cardiovascular risk and reflects possible pathogenetic
processes, which may relate to specific organisms or to
general pathogen burdens.21,22 However, the CRP was
not related to kava use and neither were homocysteine
levels, another cardiovascular risk marker, which were
also generally elevated.
In conclusion, some health effects of kava use such as
abnormal liver function, kava dermopathy and decreased
lymphocytes were observed in the present study. Moni-
toring these parameters will be useful as changes occur
in licensing and distribution of kava. Further research is
required to address concerns about possible associations
of heavy kava use in Arnhem Land with various infec-
tious diseases, especially melioidosis. Some of our results
were confounded by concomitant alcohol use and the
effects of using kava in combination with other
substances requires further analysis. The general
increase in IgE and IgG levels and CRP reflect the
burden of infectious pathogens associated with the
continuing socioeconomic disadvantage of those living in
remote Aboriginal communities. Elevated CRP is
increasingly recognized as a marker of risk for cardio-
vascular disease, and the generally high levels of CRP
and homocysteine across all groups in this Aboriginal
community are of great concern.
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